

# Investigation Report on China Bevacizumab Market, 2009-2018

<https://marketpublishers.com/r/I8967589A8BEN.html>

Date: February 2014

Pages: 40

Price: US\$ 1,800.00 (Single User License)

ID: I8967589A8BEN

## Abstracts

Bevacizumab is an important kind of remedy for metastatic colon cancer, which belongs to humanized anti-VEGF monoclonal antibody. Approved by FDA, bevacizumab came into the market in 2004, with the brand name of 'Avastin'. Its main mechanism is to inhibit the function of a natural protein called vascular endothelial growth factor (VEGF) that stimulates new blood vessel formation through specific binding so as to stop or delay growth of blood vessels in tumor, disconnect the delivery of oxygen and other nutrition necessary in tumor cells' growth, as well as to improve the effect of chemotherapy remedy. Public data shows that the global sales value of bevacizumab in 2012 exceeded USD 6.3 billion, ranking the fourth among the 10 best selling monoclonal antibody drugs.

As Chinese economy develops rapidly, Chinese people's lifestyle is changing tremendously. With the aging level increasing, environment pollution worsening, the incidence of cancer in China keeps rising. Statistics indicate that the annual increase of cancer patients in China takes up over 20% of the global, making China a capital antitumor remedy market of the world. Shanghai Roche Pharmaceuticals Ltd. declared on May 7, 2010 that its bevacizumab injection (brand name 'Avastin') was approved by the FDA for curing metastatic colorectal cancer. It is the official entry of the world's first angiogenesis inhibitor into Chinese market. The market investigation of CRI manifests that the sales value of Avastin in certain Chinese sample hospitals in 2010 was merely CNY 10 million, growing rapidly. It broke through CNY 200 million in 2013.

There have been some generic drug manufacturers developing bevacizumab around the world. At the end of 2013, Huahai Pharmaceutical in China announced that its bevacizumab generic drug developed with Oncobiologics Company was approved to conduct the first clinical trial in the European Union.

Some study declared that the combination of bevacizumab and chemotherapy can prolong overall survival time of advanced cervical cancer patients. This result indicates the possibility of this remedy with the annual sales value of USD 1 billion to treat cervical cancer.

**Through this report, the readers can acquire the following information:**

Market Share of Major Bevacizumab Manufacturers in Sample Hospitals in China

Sales price of Bevacizumab in Hospital Market in China

Share of Bevacizumab in Different Dosage Forms in Hospital Market in China

Incidence of Cancer in China

Manufacturing Schedule of Bevacizumab generic drug

Prospect of China Bevacizumab Market

**The author recommends the report to the following:**

Manufacturers of Crude and Finished Monoclonal Antibody Remedy

Medical Institutions

Investors/Research Institutes Focusing on Bevacizumab Market

## Contents

### **1 RELEVANT CONCEPTS OF BEVACIZUMAB**

- 1.1 Indication
- 1.2 Sales Status on the Global Market

### **2 MARKET OVERVIEW OF BEVACIZUMAB IN CHINA, 2010-2013**

- 2.1 Patent Status
- 2.2 Major Manufacturers
- 2.3 Market Size

### **3 INVESTIGATION ON SALES VALUE OF BEVACIZUMAB IN CHINA, 2010-2013**

- 3.1 Total Sales Value
- 3.2 Sales Value by Region

### **4 INVESTIGATION ON MARKET SHARE OF MAJOR BEVACIZUMAB MANUFACTURERS IN CHINA, 2010-2013**

- 4.1 Market Share by Sales Value
- 4.2 Market Share by Sales Volume

### **5 INVESTIGATION ON MARKET SIZE OF BEVACIZUMAB BY DOSAGE FORM IN CHINA, 2010-2013**

- 5.1 Market Share by Sales Value and Dosage Form
- 5.2 Market Share by Sales Volume and Dosage Form

### **6 REFERENCE PRICE OF BEVACIZUMAB IN HOSPITAL MARKET IN CHINA, 2010-2013**

- 6.1 Shanghai Roche Pharmaceuticals Ltd.
- 6.2 GENENTECH

### **7 PROSPECT OF CHINA BEVACIZUMAB MARKET, 2014-2018**

- 7.1 Forecast on Incidence of Cancer

7.2 Forecast on Market Size

7.3 Forecast on Competition Pattern

## Selected Charts

### SELECTED CHARTS

Chart Bevacizumab Products Approved to Market in China, 2014  
Chart Forecast on Market Size of Hospital-use Bevacizumab in China, 2014-2018  
Chart Global Sales Value of Bevacizumab, 2010-2013  
Chart Sales Value of Bevacizumab in Hospital Market in China, 2010-2013  
Chart Sales Value of Bevacizumab by Region in China, 2010-2013  
Chart Market Share of Bevacizumab Enterprises by Sales Value in China, 2010-2013  
Chart Price of Bevacizumab Produced by GENENTECH(US) in Hospital Market  
Chart Price of Bevacizumab Produced by Shanghai Roche in Hospital Market, 2010-2013

## I would like to order

Product name: Investigation Report on China Bevacizumab Market, 2009-2018

Product link: <https://marketpublishers.com/r/l8967589A8BEN.html>

Price: US\$ 1,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l8967589A8BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970